Objective： To investigate the effects of rosiglitazone, a synthetic ligand of peroxisome proliferators-activated receptor gamma （PPARγ）, on the expression of acyl-coenzyme A： cholesterol acyltransferase-1 （ACAT-...Objective： To investigate the effects of rosiglitazone, a synthetic ligand of peroxisome proliferators-activated receptor gamma （PPARγ）, on the expression of acyl-coenzyme A： cholesterol acyltransferase-1 （ACAT-1） in phorbol myristate acetate （PMA）-pretreated THP-1 cells after the inducement of advanced glycation end products （AGEs）. Methods： After THP-1 cells were cultured in the presence of 0.1 μmol/L PMA for 72 h to induce phagocytic differentiation, the obtained THP-1 macrophages were treated with rosiglitazone for 4 h at different concentrations （1, 5 or 10 μmol/L） and then exposed to AGEs-modified bovine serum albumin （AGEs-BSA） for 24 h at a concentration of 200 mg/L. Reverse transcription polymerase chain reaction （RT-PCR） and Western blot analysis were performed to detect the mRNA and protein expressions of ACAT-1 respectively. Results： Administration of AGEs-BSA （200 mg/L） into the THP-1 macrophages resulted in up-regulation of ACAT-1 at mRNA and protein levels when compared with the expressions in macrophages incubated with serum-free RPMI1640. Pretreatment of rosiglitazone inhibited significantly the increased expression of ACAT-1 induced by AGEs-BSA in a concentration-dependent manner. Conclusion： PPARy activation by rosiglitazone down-regulates ACAT-1 expression induced by AGEs in THP-1 macrophages, which might provide a new way for treating atherogenesis in diabetic patients.展开更多
The enzymes of the acyl-coenzyme A:cholesterol acyltransferase(ACAT)family are responsible for the in vivo synthesis of neutral lipids.They are potential drug targets for the intervention of atherosclerosis,hyperlipid...The enzymes of the acyl-coenzyme A:cholesterol acyltransferase(ACAT)family are responsible for the in vivo synthesis of neutral lipids.They are potential drug targets for the intervention of atherosclerosis,hyperlipidemia,obesity,type II diabetes and even Alzheimer’s disease.ACAT family enzymes are integral endoplasmic reticulum(ER)membrane proteins and can be divided into ACAT branch and acyl-coenzyme A:diacylglycerol acyltransferase 1(DGAT1)branch according to their substrate specificity.The ACAT branch catalyzes synthesis of cholesteryl esters using long-chain fatty acyl-coenzyme A and cholesterol as substrates,while the DGAT1 branch catalyzes synthesis of triacylglycerols using fatty acylcoenzyme A and diacylglycerol as substrates.In this review,we mainly focus on the recent progress in the structural research of ACAT family enzymes,including their disulfide linkage,membrane topology,subunit interaction and catalysis mechanism.展开更多
文摘Objective： To investigate the effects of rosiglitazone, a synthetic ligand of peroxisome proliferators-activated receptor gamma （PPARγ）, on the expression of acyl-coenzyme A： cholesterol acyltransferase-1 （ACAT-1） in phorbol myristate acetate （PMA）-pretreated THP-1 cells after the inducement of advanced glycation end products （AGEs）. Methods： After THP-1 cells were cultured in the presence of 0.1 μmol/L PMA for 72 h to induce phagocytic differentiation, the obtained THP-1 macrophages were treated with rosiglitazone for 4 h at different concentrations （1, 5 or 10 μmol/L） and then exposed to AGEs-modified bovine serum albumin （AGEs-BSA） for 24 h at a concentration of 200 mg/L. Reverse transcription polymerase chain reaction （RT-PCR） and Western blot analysis were performed to detect the mRNA and protein expressions of ACAT-1 respectively. Results： Administration of AGEs-BSA （200 mg/L） into the THP-1 macrophages resulted in up-regulation of ACAT-1 at mRNA and protein levels when compared with the expressions in macrophages incubated with serum-free RPMI1640. Pretreatment of rosiglitazone inhibited significantly the increased expression of ACAT-1 induced by AGEs-BSA in a concentration-dependent manner. Conclusion： PPARy activation by rosiglitazone down-regulates ACAT-1 expression induced by AGEs in THP-1 macrophages, which might provide a new way for treating atherogenesis in diabetic patients.
文摘The enzymes of the acyl-coenzyme A:cholesterol acyltransferase(ACAT)family are responsible for the in vivo synthesis of neutral lipids.They are potential drug targets for the intervention of atherosclerosis,hyperlipidemia,obesity,type II diabetes and even Alzheimer’s disease.ACAT family enzymes are integral endoplasmic reticulum(ER)membrane proteins and can be divided into ACAT branch and acyl-coenzyme A:diacylglycerol acyltransferase 1(DGAT1)branch according to their substrate specificity.The ACAT branch catalyzes synthesis of cholesteryl esters using long-chain fatty acyl-coenzyme A and cholesterol as substrates,while the DGAT1 branch catalyzes synthesis of triacylglycerols using fatty acylcoenzyme A and diacylglycerol as substrates.In this review,we mainly focus on the recent progress in the structural research of ACAT family enzymes,including their disulfide linkage,membrane topology,subunit interaction and catalysis mechanism.
